Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
TERMINATED
NCT04865458
PHASE1
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
Sponsor: Sunshine Lake Pharma Co., Ltd.
View on ClinicalTrials.gov
Summary
Evaluate the safety, pharmacokinetics and efficacy of HEC89736 in patients with Relapsed or Refractory B-cell Hematologic Malignancies
Official title: A Phase I Single Arm,Open-label,Multiple Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2021-04-01
Completion Date
2022-09-21
Last Updated
2026-05-14
Healthy Volunteers
No
Interventions
DRUG
HEC89736
HEC89736 tablets QD every 28 days for each cycle
Locations (2)
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China